Navigation Links
Soligenix to Present at 13th Annual BIO CEO & Investor Conference
Date:2/9/2011

PRINCETON, N.J., Feb. 9, 2011 /PRNewswire/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 2011 BIO CEO & Investor Conference on Monday, February 14, at 9:00 AM Eastern Standard Time.  The presentation will take place in the Duke of Windsor Room at the Waldorf Astoria Hotel in New York City.

The Soligenix presentation will be webcast live and archived for later replay. To access the webcast, please visit the company's investor page at http://www.soligenix.com/invest_sec.shtml.  A replay of the presentation will be archived after the conference at the same location.

For more information about the 2011 BIO CEO & Investor Conference, please refer to the conference website at http://www.bio.org/bioceo/.

About Soligenix, Inc.

Soligenix is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation. orBec® is currently the subject of a $1.2 million FDA Orphan Products Grant-supported confirmatory Phase 3 clinical trial for the treatment of acute GI GVHD. Soligenix is also conducting a National Cancer Institute (NCI)-supported Phase 1/2 clinical trial of SGX201 in the prevention of acute radiatio
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
9. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
10. Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
11. Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/23/2014)... 2014 The American Society for Radiation Oncology (ASTRO) ... Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO ... radiation therapy in the treatment of endometrial cancer. ... May-June 2014 issue of Practical Radiation Oncology ... ASTRO. The full-length guideline is available as an ...
(Date:4/23/2014)... enzyme pathway that helps prevent new cells from receiving ... has been directly linked to cancer and other diseases. ... near the end of cell division, the enzyme Cdc14 ... DNA are fully repaired before the parent cell distributes ... helps safeguard against some of the most devastating genome ...
(Date:4/23/2014)... falls below normal levels are more likely to have ... disease and type 2 diabetes. A new simple screening ... and possible treatment is described in an article in ... from Mary Ann Liebert, Inc., publishers. The article is ... website at http://www.liebertpub.com/jmh . , ...
(Date:4/23/2014)... 2014) The American Gastroenterological Association (AGA) Research ... Research Scholars. The AGA Research Scholar Awards program, ... independent and productive research careers in digestive diseases. ... an additional year allowing for three consecutive years ... junior faculty who are paving the way for ...
(Date:4/23/2014)... country as wealthy as the United States, it may come ... have access to adequate food due to lack of money ... Recent research at the University of Illinois using data from ... the seniors who are dealing with hunger are also facing ... percent of Americans over age 60 faced the threat of ...
Breaking Medicine News(10 mins):Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:More Americans in their golden years are going hungry 2
... Program and Its Impact on ... Meth Use in Montana, PALO ... the Finance Committee of the,United States Senate today. Siebel was invited to ... the state of Montana --,where the Meth Project implemented its first statewide ...
... WHITE PLAINS, N.Y., Sept. 18 Lynn Clark,Callister, ... Brigham Young,University, has joined the March of Dimes ... internationally recognized nursing leaders who,give direction and counsel ... "March of Dimes Nurse Advisory Council members represent ...
... ViroPharma Incorporated,(Nasdaq: VPHM ) today announced that ... will present at the UBS Global Life,Sciences Conference at ... is being held at the Grand Hyatt in New ... investors through, http://www.viropharma.com and available through October 4, ...
... Suite operates with Gryphon compliance services ... in increased productivity for call centers, OKLAHOMA ... of,intelligent customer interaction solutions, today announced that it ... worldwide leader in,On-Demand Contact Governance solutions. This agreement ...
... Beginning Oct. 14, the,Appleton Museum of Art and ... personal mementos owned by Princess Diana. (Photo: ... of Wales: Dresses for a Cause," the exhibit,will ... by the princess,featuring 30 designer dresses. Event partnerships ...
... Inc. (OTCBB: PVCT) announced preliminary results of its Phase ... metastatic melanoma, the most aggressive form of skin cancer. ... effect on melanoma tumors in stage III patients. The ... total of 20 subjects at two sites in Australia. ...
Cached Medicine News:Health News:Meth Project Chairman Testifies Before U.S. Senate Finance Committee 2Health News:Meth Project Chairman Testifies Before U.S. Senate Finance Committee 3Health News:Lynn Clark Callister, National Leader in Maternal-Child Health Nursing, Joins March of Dimes Advisory Council 2Health News:Amcat Partners With Gryphon to Provide Comprehensive and Guaranteed Do Not Call (DNC) Compliance Solution for Outbound Contact Activities 2Health News:Amcat Partners With Gryphon to Provide Comprehensive and Guaranteed Do Not Call (DNC) Compliance Solution for Outbound Contact Activities 3Health News:World's Largest Exhibit of Princess Diana's Dresses Hosted by Appleton Museum 2Health News:Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study 2
... designed for patient comfort as well as dependable ... at 5cm intervals and line marked each centimeter., ... available spanning most clinical needs and the range ... or two sensors., ,Flexilog single-use catheters are ...
... for 24-hour esophageal pH monitoring. , ... are reusable up to five times. ... same high quality materials as the ... available in many configurations., ,Contact ...
... VersaFlex™ disposable pH catheter is used ... worldwide for evaluating acid reflux events., ... esophageal pH monitoring. , ,Alpine's ... esophageal catheter on the market (4.7 ...
... single-use pH catheters are efficient, economical, ... allow greater patient comfort during the ... measurement systems have been designed to ... an accurate room-temperature calibration. The temperature ...
Medicine Products: